[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Immunology](https://durgical.com/en/immunology/) › [Transplant, tumors and immunotherapy](https://durgical.com/en/immunology/areas/transplant/) › Treating antibody diseases: IVIG, plasma exchange, B-cell depletion

# Treating antibody diseases: IVIG, plasma exchange, B-cell depletion

- Topic

When the body's own [antibodies](https://durgical.com/en/biochemistry/enzymes/immunoglobulins/) cause the disease, you can dilute them, wash them out of the blood or shut down the cells that make them.

Updated Nov 15, 2026

## Key points

- [IVIG](https://durgical.com/en/pharmacology/normal-human-immunoglobulin/): replacement (low dose) vs immunomodulation (high dose); key in Kawasaki and ITP.
- Plasma exchange removes antibodies fast: [myasthenic crisis](https://durgical.com/en/neurology/myasthenic-crisis/), Guillain–Barré, anti-GBM, TTP.
- [Rituximab](https://durgical.com/en/pharmacology/rituximab/) spares plasma cells → slow effect; check hepatitis B.
- FcRn blockade lowers all IgG.
- [Complement inhibitors](https://durgical.com/en/pharmacology/classes/complement-inhibitors/) → vaccinate against [meningococcus](https://durgical.com/en/microbiology/neisseria-meningitidis/).

On this page

- The basics Key points
- What it is
- How to think about it
- Key facts
- Step by step
- Common traps
- Elsewhere in DurgiPedia

- Clinical Ways to treat antibody-mediated disease
- Clinical notes

- Study Test yourself

- Connections Connections

## What it is

Diseases caused by autoantibodies or alloantibodies ([myasthenia gravis](https://durgical.com/en/conditions/myasthenia-gravis/), Guillain–Barré syndrome, [immune thrombocytopenia](https://durgical.com/en/conditions/immune-thrombocytopenia/), [pemphigus](https://durgical.com/en/general-pathology/pemphigus/), [anti-GBM disease](https://durgical.com/en/conditions/rapidly-progressive-glomerulonephritis/)) are treated by lowering or neutralising the harmful antibody. Intravenous immunoglobulin (IVIG) both replaces antibody in immunodeficiency and modulates immunity at high doses; plasma exchange physically removes antibodies; B-cell depletion with anti-CD20 stops new production more slowly. Newer drugs block FcRn or complement.

## How to think about it

Think of a harmful antibody as water in a leaking tank: plasma exchange bails it out (fast, but the tap keeps running), IVIG and FcRn blockers open the drain wider, and anti-CD20 turns down the tap. The exception is the long-lived plasma cell, a tap anti-CD20 cannot reach, so its effect is slow and partial.

## Key facts

- FcRn normally rescues IgG from degradation, giving IgG its long half-life; flooding or blocking it shortens the life of all IgG, including autoantibodies.
- In TTP, plasma exchange both removes the anti-ADAMTS13 antibody and supplies the missing enzyme.
- [Glucocorticoids](https://durgical.com/en/physiology/actions-of-cortisol/) and other immunosuppressants are usually given alongside these treatments to lower new antibody production.

## Step by step

- Plasma cells secrete IgG; FcRn on endothelium rescues IgG from lysosomes, which is why IgG lasts weeks.
- Plasma exchange removes plasma, so circulating IgG and immune complexes fall within days.
- IgG then rebounds as plasma cells keep secreting and tissue IgG re-enters the blood, so exchange is a bridge, not a cure.
- IVIG floods FcRn and FcRn blockers occupy it, so all IgG, including the autoantibody, is degraded faster.
- IVIG also blocks Fc receptors on splenic macrophages, which is why platelets rise quickly in ITP.
- Anti-CD20 removes B cells, so new plasma cells stop forming; old plasma cells (CD20⁻) fade over months.

## Ways to treat antibody-mediated disease

| Approach | How it works | Typical uses | Cautions |
| --- | --- | --- | --- |
| IVIG (pooled IgG from many donors) | Saturates FcRn (faster loss of pathogenic IgG), blocks Fc receptors on macrophages, neutralises antibodies and complement | [Kawasaki disease](https://durgical.com/en/conditions/kawasaki-disease/), immune thrombocytopenia, Guillain–Barré, [CIDP](https://durgical.com/en/conditions/chronic-inflammatory-demyelinating-polyneuropathy/), myasthenic crisis; replacement in XLA and [CVID](https://durgical.com/en/conditions/common-variable-immunodeficiency/) | Headache, [aseptic meningitis](https://durgical.com/en/conditions/viral-meningitis/), thrombosis, kidney injury, haemolysis; [anaphylaxis](https://durgical.com/en/conditions/anaphylaxis/) risk with anti-IgA antibodies |
| Plasma exchange | Removes plasma with antibodies and immune complexes, replaced with [albumin](https://durgical.com/en/biochemistry/enzymes/albumin/) or plasma | Myasthenic crisis, Guillain–Barré, anti-GBM disease, TTP, hyperviscosity | Needs vascular access; hypotension, [citrate](https://durgical.com/en/biochemistry/molecules/citrate/) -related low calcium, loss of [clotting factors](https://durgical.com/en/physiology/the-coagulation-cascade/) |
| Anti-CD20 B-cell depletion | Kills CD20⁺ B cells; plasma cells are spared, so effect is slow | Pemphigus, ANCA vasculitis, some myasthenia, neuromyelitis optica, ITP | Hepatitis B reactivation, infections, rarely PML; poor vaccine responses |
| FcRn blockers | Stop IgG recycling so IgG levels fall | Generalised myasthenia gravis | Lower IgG for all specificities |
| Complement inhibitors | Block C5 so antibodies cannot cause complement injury | Myasthenia, neuromyelitis optica, atypical HUS, PNH | Meningococcal infection risk: vaccinate first |

## Clinical notes

- Kawasaki disease: IVIG early in the illness lowers the risk of coronary artery aneurysms.
- Patients with [selective IgA deficiency](https://durgical.com/en/conditions/selective-iga-deficiency/) may have anti-IgA antibodies and react to blood products or IVIG.
- Screen for hepatitis B before anti-CD20 therapy.
- Nursing: infuse IVIG slowly at first and watch for infusion reactions and signs of thrombosis.

## Common traps

- **Rituximab clears autoantibodies quickly**: it spares CD20-negative plasma cells, so antibody levels fall over months, not days.
- **Plasma exchange is a lasting fix**: antibody rebounds within days to weeks unless production is also suppressed.
- **IVIG is the same treatment in CVID and in Kawasaki disease**: low-level replacement in CVID, high-level immunomodulation in Kawasaki or ITP.
- **FcRn blockers lower only the harmful antibody**: they lower all IgG, so protective antibodies fall too.
- **IVIG is safe in any IgA-deficient patient**: those with anti-IgA antibodies can have anaphylaxis to IgA traces in it.

## Test yourself

Think of the answer, then tap the question to see it.

## A child with Kawasaki disease gets IVIG early in the illness. What complication is it meant to prevent, and why does timing matter?

Coronary artery aneurysms; IVIG damps the vasculitis before the arterial wall is permanently damaged, so late treatment helps less.

## Why does anti-CD20 therapy lower autoantibody levels only slowly?

It removes B cells but not long-lived plasma cells, which lack CD20 and keep secreting antibody.

## In myasthenic crisis, why is plasma exchange chosen over rituximab?

Exchange removes circulating antibody within days; rituximab only stops new production and takes months to act.

## Which vaccination is required before starting a complement C5 inhibitor, and why?

Meningococcal vaccination, because blocking C5 removes the membrane attack complex needed to kill Neisseria.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/immunology/treating-antibody-diseases-ivig-plasma-exchange-b-cell-depletion/)

## Elsewhere in DurgiPedia

- [Myasthenia gravis: the neuromuscular junction](https://durgical.com/en/general-pathology/myasthenia-gravis-the-neuromuscular-junction/)
- [Guillain–Barré syndrome and CIDP](https://durgical.com/en/general-pathology/guillain-barre-syndrome-and-cidp/)
- [Immune thrombocytopenias: ITP and HIT](https://durgical.com/en/general-pathology/immune-thrombocytopenias-itp-and-hit/)

## Connections

## Related 8

- [Type II hypersensitivity (antibody against cells)](https://durgical.com/en/immunology/type-ii-hypersensitivity/)
- [Autoantibodies: the table to know](https://durgical.com/en/immunology/autoantibodies-the-table-to-know/)
- [Turning antibody responses off: antibody feedback and FcγRIIB](https://durgical.com/en/immunology/turning-antibody-responses-off-antibody-feedback-and-fc-riib/)
- [Monoclonal antibodies and biologics: naming and targets](https://durgical.com/en/immunology/monoclonal-antibodies-and-biologics-naming-and-targets/)
- [Complement deficiencies and hereditary angioedema](https://durgical.com/en/immunology/complement-deficiencies-and-hereditary-angioedema/)
- [Passive immunization: immunoglobulins and antitoxins](https://durgical.com/en/immunology/passive-immunization-immunoglobulins-and-antitoxins/)
- [B-cell (antibody) deficiencies: XLA, CVID, IgA deficiency, hyper-IgM](https://durgical.com/en/immunology/b-cell-deficiencies-xla-cvid-iga-deficiency-hyper-igm/)
- [Treating inborn errors of immunity: IgG, transplant, gene therapy](https://durgical.com/en/immunology/treating-inborn-errors-of-immunity-igg-transplant-gene-therapy/)

## Related conditions 6

- [Myasthenia gravis](https://durgical.com/en/conditions/myasthenia-gravis/)
- [Kawasaki disease](https://durgical.com/en/conditions/kawasaki-disease/)
- [Rapidly progressive glomerulonephritis (anti-GBM, ANCA)](https://durgical.com/en/conditions/rapidly-progressive-glomerulonephritis/)
- [Pemphigus vulgaris](https://durgical.com/en/conditions/pemphigus-vulgaris/)
- [Granulomatosis with polyangiitis](https://durgical.com/en/conditions/granulomatosis-with-polyangiitis/)
- [Common variable immunodeficiency (CVID)](https://durgical.com/en/conditions/common-variable-immunodeficiency/)

## In Pharmacology 2

- [Normal human immunoglobulin (IVIG)](https://durgical.com/en/pharmacology/normal-human-immunoglobulin/)
- [Rituximab](https://durgical.com/en/pharmacology/rituximab/)

[← All of immunology](https://durgical.com/en/immunology/)

Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.

Sources: [Antibody](https://medlineplus.gov/ency/article/002223.htm) (MedlinePlus, US National Library of Medicine, 2024); [Immunodeficiency diseases](https://medlineplus.gov/ency/article/000818.htm) (MedlinePlus, US National Library of Medicine, 2024).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/immunology/treating-antibody-diseases-ivig-plasma-exchange-b-cell-depletion/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/immunology/treating-antibody-diseases-ivig-plasma-exchange-b-cell-depletion/
